SP-0230 is under clinical development by Sanofi and currently in Phase II for Neisseria meningitidis Infections.

The emergence of Neisseria gonorrhoeae strains resistant to ceftriaxone, the last reliable treatment, poses significant ...

The disease is caused by the bacterium Neisseria gonorrhoeae. The infection is spread by unprotected vaginal, oral and anal sex. Symptoms can include a thick green or yellow discharge from sexual ...